Here, we show that metformin and trametinib synergistically decrease cell viability in a large survey of NRAS mutant melanoma, lung cancer and neuroblastoma cell lines, including two cell lines with acquired trametinib resistance. The gene discussed is NRAS; the disease is lung cancer.